F
0K9A
vs
D
DAX Index
Over the past 12 months, 0K9A has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +13% growth.
Stocks Performance
0K9A vs DAX Index
Performance Gap
0K9A vs DAX Index
Performance By Year
0K9A vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FSD Pharma Inc
Glance View
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. The company is headquartered in Toronto, Ontario and currently employs 10 full-time employees. The company went IPO on 2018-05-29. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its lead compound, FSD 201, ultra-micronized Palmitoyl (PEA). FSD 201 stabilizes mast cells of the human body and down-regulate the proinflammatory cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a subsidiary of the Company, has worldwide rights to compounds shown to prevent and reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, the Company is focused on develop a psychoactive (psychedelic-based) therapeutic of neurodegenerative disorders.
